57728-59-3

Basic information

• Product Name: (3-CHLORO-BENZOYLAMINO)-ACETIC ACID
• Synonyms: 2-[(3-CHLOROBENZOYL)AMINO]ACETIC ACID;(3-CHLORO-BENZOYLAMINO)-ACETIC ACID;TIMTEC-BB SBB004570;m-Chlorohippuric acid
• CAS NO: 57728-59-3
• Molecular Formula: C₉H₈ClNO₃
• Molecular Weight: 213.62
• Mol File: 57728-59-3.mol

Chemical Properties

• Melting Point: 144-147°C
• Boiling Point: 440.5°C at 760 mmHg
• Flash Point: 220.2°C
• Appearance: /
• Vapor Pressure: 1.55E-08mmHg at 25°C
• Storage Temp.: Refrigerator
• Solubility: DMSO (Slightly), Methanol (Slightly)
• CAS DataBase Reference: (3-CHLORO-BENZOYLAMINO)-ACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: (3-CHLORO-BENZOYLAMINO)-ACETIC ACID(57728-59-3)
• EPA Substance Registry System: (3-CHLORO-BENZOYLAMINO)-ACETIC ACID(57728-59-3)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 57728-59-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(3-CHLORO-BENZOYLAMINO)-ACETIC ACID is used as an intermediate compound for the synthesis of various pharmaceuticals, particularly those with anticonvulsant and cardiotonic properties. Its molecular structure allows for further chemical modifications to enhance its therapeutic effects and target specific medical conditions.
Used in Chemical Research:
In the field of chemical research, (3-CHLORO-BENZOYLAMINO)-ACETIC ACID serves as a valuable compound for studying the effects of chloro and amino substitutions on the chemical and biological properties of acetic acid derivatives. This can lead to the development of new compounds with improved characteristics and applications.
Used in Drug Metabolism Studies:
(3-CHLORO-BENZOYLAMINO)-ACETIC ACID, being a metabolite of certain drugs, is used in drug metabolism studies to understand the biotransformation processes in the body. This knowledge can be applied to optimize drug dosages, reduce side effects, and improve the overall efficacy of medications.

InChI:InChI=1/C9H8ClNO3/c10-7-3-1-2-6(4-7)9(14)11-5-8(12)13/h1-4H,5H2,(H,11,14)(H,12,13)/p-1

Upstream product

• 495-69-2 Hippuric Acid 
• 618-46-2 m-Chlorobenzoyl chloride 
• 56-40-6 glycine 
• 7647-01-0 hydrogenchloride 
• 535-80-8 3-chlorobenzoate 
• 75152-20-4 2-(3-chloro-phenyl)-4H-oxazol-5-one 

Downstream Products

• 98386-17-5 (3-Chlorbenzoyloxy)essigsaeure 
• 535-80-8 3-chlorobenzoate 
• 75152-13-5 (3-Chloro-benzoylamino)-acetic acid 4-nitro-phenyl ester 
• 56-40-6 glycine 
• 904664-95-5 2-(3-chlorophenyl)-4-(2-nitrobezylidene)-4,5-dihydrooxazol-5-one 
• 89242-16-0 C₁₆H₁₀ClNO₂ 
• 657424-68-5 5-(3-chloro-phenyl)-[1,2,4]oxadiazole-3-carboxylic acid ethyl ester 
• 1072875-30-9 C₁₉H₁₇Cl₂N₃O₃ 
• 373618-95-2 2-(3-chloro-phenyl)-4-dimethylaminomethylene-4H-oxazol-5-one 
• 1026563-98-3 [(3-chlorobenzoyl)amino]methyl acetate 
• 205925-52-6 (Z)-2-(3-chlorobenzoylamino)-N-butyl-3-(4-chlorophenyl)-2-propenamide 
• 904665-10-7 N-[1-hydrazinocarbonyl-2-(2-nitrophenyl)vinyl]-3-chlorobenzamide 
• 904665-16-3 N-[2-(2-aminophenyl)-1-hydrazinocarbonylvinyl]-3-chlorobenzamide 
• 904665-32-3 3-(3-chlorophenyl)-5-(2-aminobenzyl)-1H-[1,2,4]triazin-6-one 

Relevant articles and documents

MAGL inhibitor as well as preparation method and application thereof

The invention relates to a compound shown as a formula I in the description and a pharmaceutically acceptable salt thereof, a preparation method, an intermediate for preparing the compound, a composition containing the compound or salt, and application of

Synthesis and evaluation of new phenyl acrylamide derivatives as potent non-nucleoside anti-HBV agents

As a continuation of our previous work, a series of new phenyl acrylamide derivatives (4Aa-g, 4Ba-t, 5 and 6a-c) were designed and synthesized as non-nucleoside anti-HBV agents. Among them, compound 4Bs could potently inhibit HBV DNA replication in wild-type and lamivudine (3TC)/entecavir resistant HBV mutant strains with IC50 values of 0.19 and 0.18 μM, respectively. Notably, the selective index value of 4Bs was above 526, indicating the favorable safety profile. Interestingly, unlike nucleoside analogue 3TC, 4Bs could significantly inhibit 3.5 kb pgRNA expression. Molecular docking study revealed that 4Bs could fit well into the dimer-dimer interface of HBV core protein by hydrophobic, π–π and H-bond interactions. Considering the potent anti-HBV activity, low toxicity and diverse anti-HBV mechanism from that of nucleoside anti-HBV agent 3TC, compound 4Bs might be a promising lead to develop novel non-nucleoside anti-HBV therapeutic agents, and warranted further investigation.

Substituted [1,2,4]triazolo[4,3-a]pyrazines as antidiabetics

Compounds for the treatment of hyperglycemia and/or diabetes are provided. The compounds, which inhibit the enzyme dipeptidyl peptidase (DPP-4), are based on the structure where n1=0-2 such as 0 or 1; R1 is i) a saturated or unsaturated, substituted or un

4-Sulfamoylphenylalkylamides as Inhibitors of Carbonic Anhydrases Expressed in Vibrio cholerae

A current issue of antimicrobial therapy is the resistance to treatment with worldwide consequences. Thus, the identification of innovative targets is an intriguing challenge in the drug and development process aimed at newer antimicrobial agents. The state-of-art of anticholera therapy might comprise the reduction of the expression of cholera toxin, which could be reached through the inhibition of carbonic anhydrases expressed in Vibrio cholerae (VchCAα, VchCAβ, and VchCAγ). Therefore, we focused our interest on the exploitation of sulfonamides as VchCA inhibitors. We planned to design and synthesize new benzenesulfonamides based on our knowledge of the VchCA catalytic site. The synthesized compounds were tested thus collecting useful SAR information. From our investigation, we identified new potent VchCA inhibitors, some of them displayed high affinity toward VchCAγ class, for which few inhibitors are currently reported in literature. The best interesting VchCAγ inhibitor (S)-N-(1-oxo-1-((4-sulfamoylbenzyl)amino)propan-2-yl)furan-2-carboxamide (40) resulted more active and selective inhibitor when compared with acetazolamide (AAZ) as well as previously reported VchCA inhibitors.

MAGL inhibitor and preparation method and application thereof

The invention belongs to the field of medicines, and relates to a compound and a pharmaceutically acceptable salt thereof, a preparation method thereof, a composition containing the compound or the salt, and their use in the treatment of MAGL-mediated dis

A convenient method for synthesis of 5-chloro-2-aryloxazole-4-carbaldehyde with vilsmeier reagent

A convenient method for synthesis of 5-chloro-2-aryloxazole-4-carbaldehyde 3 in moderate to good yields had been developed via the Vilsmeier reaction of readily available N-arylglycine 2 at 100 °C, provided a novel route for the construction of nitrogen heterocycles. A series of these compounds were synthesized by this method and optimization of conditions was performed. The Japan Institute of Heterocyclic Chemistry.

Structure-Reactivity Studies on the Equilibrium Reaction between Phenolate Ions and 2-Aryloxazolin-5-ones: Data Consistent with a Concerted Acyl-Group-Transfer Mechanism

The rate and equilibrium constants for the reaction between phenolate anions and 2-aryloxazolin-5-ones have been measured as a function of the structures Ar and Ar'.The change in "effective" charge on both phenol-leaving oxygen and endocyclic oxygen from ground to transition state, as determined from the relevant Broensted parameters, is substantial and essentially additive consistent with a concerted displacement mechanism.The stepwise mechanism requires a small change in effective charge on the phenol oxygen because departure of phenolate ion from the tetrahedral intermediate cannot be rate limiting.Hydroxide ion attack on the C-5 atom of the oxazolinone to yield a benzoylglycine has a Hammett ?- dependence which can only arise from a concerted displacement; the rate-limiting step for the stepwise mechanism is the addition of hydroxide and the transition state of the rate-limiting step will therefore not involve much endocyclic C-O bond fission.An inverse deuterium oxide solvent isotope effect indicates that the observed general-acid catalysis has a specific-acid/nucleophilic mechanism; both hydroxide and oxonium ion catalysis are demonstrated by using 18O-labeling experiments to involve nucleophilic attack at the carbonyl (C-5) center.The equilibrium constant for reaction of azide ion with 2-phenyloxazolin-5-ones has been measured; it is suggested that the absence of racemization during azide coupling in peptide synthesis is related to the very unfavorable equilibrium constant for oxazolinone formation compared with that of activated oxygen esters.